<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">34771040</PMID>
      <DateCompleted>
        <Year>2021</Year>
        <Month>12</Month>
        <Day>03</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2021</Year>
        <Month>12</Month>
        <Day>14</Day>
      </DateRevised>
      <Article PubModel="Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1420-3049</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>26</Volume>
            <Issue>21</Issue>
            <PubDate>
              <Year>2021</Year>
              <Month>Nov</Month>
              <Day>01</Day>
            </PubDate>
          </JournalIssue>
          <Title>Molecules (Basel, Switzerland)</Title>
          <ISOAbbreviation>Molecules</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Warfarin Sodium Stability in Oral Formulations.</ArticleTitle>
        <ELocationID EIdType="pii" ValidYN="Y">6631</ELocationID>
        <ELocationID EIdType="doi" ValidYN="Y">10.3390/molecules26216631</ELocationID>
        <Abstract>
          <AbstractText>Warfarin sodium is a low-dose pharmaceutical blood thinner that exists in two forms: the clathrate form and the amorphous form. In commercially available warfarin sodium oral suspension, the active pharmaceutical ingredient (API) is added in the amorphous state. This study investigates the apparent instability of the commercially available warfarin liquid oral formulation using Raman and IR spectroscopy, X-ray diffraction, differential scanning calorimetry, UV spectroscopy, and optical microscopy. Warfarin, not its sodium salt, was identified as the undissolved solid existing in the suspension. This was found to be due to the dissociation of sodium salt and the protonation of the warfarin ion in the liquid phase, which triggered the crystallization of the sparingly soluble unsalted form. The coexistence of protonated and unprotonated warfarin ions in the supernatant, as detected by Raman and UV spectroscopy, confirmed this assumption. Study of the dissolution of warfarin sodium amorphous salt and crystalline sodium clathrate in the placebo and pure water verified the results. The effect of pH and temperature on warfarin precipitation was also explored.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Dimitrokalli</LastName>
            <ForeName>Evangelia</ForeName>
            <Initials>E</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pharmacy, University of Patras, GR-26504 Rio Achaias, Greece.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Fertaki</LastName>
            <ForeName>Stefani</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pharmacy, University of Patras, GR-26504 Rio Achaias, Greece.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Institute of Chemical Engineering Sciences, Foundation of Research and Technology-Hellas (ICE-HT/FORTH), GR-26504 Platani Achaias, Greece.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Lykouras</LastName>
            <ForeName>Michail</ForeName>
            <Initials>M</Initials>
            <Identifier Source="ORCID">0000-0001-7864-0911</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Pharmacy, University of Patras, GR-26504 Rio Achaias, Greece.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kokkinos</LastName>
            <ForeName>Petros</ForeName>
            <Initials>P</Initials>
            <AffiliationInfo>
              <Affiliation>Institute of Chemical Engineering Sciences, Foundation of Research and Technology-Hellas (ICE-HT/FORTH), GR-26504 Platani Achaias, Greece.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Orkoula</LastName>
            <ForeName>Malvina</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pharmacy, University of Patras, GR-26504 Rio Achaias, Greece.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kontoyannis</LastName>
            <ForeName>Christos</ForeName>
            <Initials>C</Initials>
            <Identifier Source="ORCID">0000-0003-0452-1957</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Pharmacy, University of Patras, GR-26504 Rio Achaias, Greece.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Institute of Chemical Engineering Sciences, Foundation of Research and Technology-Hellas (ICE-HT/FORTH), GR-26504 Platani Achaias, Greece.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2021</Year>
          <Month>11</Month>
          <Day>01</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Molecules</MedlineTA>
        <NlmUniqueID>100964009</NlmUniqueID>
        <ISSNLinking>1420-3049</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>5Q7ZVV76EI</RegistryNumber>
          <NameOfSubstance UI="D014859">Warfarin</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000284" MajorTopicYN="N">Administration, Oral</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004339" MajorTopicYN="N">Drug Compounding</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004355" MajorTopicYN="N">Drug Stability</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015394" MajorTopicYN="N">Molecular Structure</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010316" MajorTopicYN="N">Particle Size</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014859" MajorTopicYN="N">Warfarin</DescriptorName>
          <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>
          <QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">DSC</Keyword>
        <Keyword MajorTopicYN="N">IR</Keyword>
        <Keyword MajorTopicYN="N">Raman spectroscopy</Keyword>
        <Keyword MajorTopicYN="N">X-ray powder diffraction</Keyword>
        <Keyword MajorTopicYN="N">crystallization</Keyword>
        <Keyword MajorTopicYN="N">oral suspension</Keyword>
        <Keyword MajorTopicYN="N">warfarin</Keyword>
        <Keyword MajorTopicYN="N">warfarin clathrate</Keyword>
        <Keyword MajorTopicYN="N">warfarin sodium amorphous</Keyword>
      </KeywordList>
      <CoiStatement>The authors declare no conflict of interest.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2021</Year>
          <Month>8</Month>
          <Day>26</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2021</Year>
          <Month>10</Month>
          <Day>22</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2021</Year>
          <Month>10</Month>
          <Day>30</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2021</Year>
          <Month>11</Month>
          <Day>13</Day>
          <Hour>1</Hour>
          <Minute>13</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2021</Year>
          <Month>11</Month>
          <Day>14</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2021</Year>
          <Month>12</Month>
          <Day>15</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>epublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">34771040</ArticleId>
        <ArticleId IdType="pmc">PMC8588291</ArticleId>
        <ArticleId IdType="doi">10.3390/molecules26216631</ArticleId>
        <ArticleId IdType="pii">molecules26216631</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Yu L. Amorphous pharmaceutical solids: Preparation, characterization and stabilization. Adv. Drug Deliv. Rev. 2001;48:27–42. doi: 10.1016/S0169-409X(01)00098-9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0169-409X(01)00098-9</ArticleId>
            <ArticleId IdType="pubmed">11325475</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Qiu J., Li G., Sheng Y., Zhu M. Quantification of febuxostat polymorphs using powder X-ray diffraction technique. J. Pharm. Biomed. Anal. 2015;107:298–303. doi: 10.1016/j.jpba.2015.01.005.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jpba.2015.01.005</ArticleId>
            <ArticleId IdType="pubmed">25636167</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bonfilio R., De Araujo M.B., Nunes Salgado H.R. Recent applications of analytical techniques for quantitative pharmaceutical analysis: A review. WSEAS Trans. Biol. Biomed. 2010;4:316–338.</Citation>
        </Reference>
        <Reference>
          <Citation>Rahman Z., Korang-Yeboah M., Siddiqui A., Mohammad A., Khan M.A. Understanding effect of formulation and manufacturing variables on the critical quality attributes of warfarin sodium product. Int. J. Pharm. 2015;495:19–30. doi: 10.1016/j.ijpharm.2015.08.065.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ijpharm.2015.08.065</ArticleId>
            <ArticleId IdType="pubmed">26319638</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>European Pharmacopoeia 10.5  04/2014:0699. Warfarin Sodium Clathrate.  [(accessed on 21 February 2021)].  Available online:  https://pheur.edqm.eu/internal/a4057e4bf5d940ea9a33865406166d09/10-5/10-5/page/0699E.pdf.</Citation>
        </Reference>
        <Reference>
          <Citation>US Pharmacopoeia  . The National Formulary, USP 24/NF19. United States Pharmacopoeia Convention; Rockville, MD, USA: 2000. </Citation>
        </Reference>
        <Reference>
          <Citation>Gao D., Maurin M.B. Physical chemical stability of warfarin sodium. AAPS Pharm. Sci. 2001;3:18–25. doi: 10.1208/ps030103.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1208/ps030103</ArticleId>
            <ArticleId IdType="pmc">PMC2751235</ArticleId>
            <ArticleId IdType="pubmed">11741254</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hiskey C., Melnitchenko V. Clathrates of Sodium Warfarin. J. Pharm. Sci. 1965;54:1298–1302. doi: 10.1002/jps.2600540916.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/jps.2600540916</ArticleId>
            <ArticleId IdType="pubmed">5881225</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gao D., Rytting J. Use of solution calorimetry to determine the extent of crystallinity of drugs and excipients. Int. J. Pharm. 1997;151:183–192. doi: 10.1016/S0378-5173(97)04895-3.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0378-5173(97)04895-3</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sheth A.R., Brennessel W.W., Young V.G., Muller F.X., Grant D.J.W. Solid-State Properties of Warfarin Sodium 2-Propanol Solvate. J. Pharm. Sci. 2004;93:2669–2679. doi: 10.1002/jps.20164.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/jps.20164</ArticleId>
            <ArticleId IdType="pubmed">15389677</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Franc A., Muselík J., Zeman J., Lukášová I., Kurhajec S., Bartoníčková E., Galvánková L., Mika F., Dominik M., Vetchýa D. The effect of amorphous and crystal sodium warfarin and its content uniformity on bioequivalence of tablets. Eur. J. Pharm. Sci. 2018;125:120–129. doi: 10.1016/j.ejps.2018.09.022.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ejps.2018.09.022</ArticleId>
            <ArticleId IdType="pubmed">30287409</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cambridge Crystallographic Data Centre  Warfarin. Deposition Number: 212540.  [(accessed on 13 October 2021)].  Available online:  https://www.ccdc.cam.ac.uk/structures/Search?Compound=warfarin&amp;DatabaseToSearch=Published.</Citation>
        </Reference>
        <Reference>
          <Citation>Cambridge Crystallographic Data Centre  Warfarin Sodium. Deposition Number: 2019436.  [(accessed on 13 October 2021)].  Available online:  https://www.ccdc.cam.ac.uk/structures/Search?Compound=sodium%20warfarin&amp;DatabaseToSearch=Published.</Citation>
        </Reference>
        <Reference>
          <Citation>Schlatter J., Cisternino S. Stability of warfarin sodium flavoured preservative-free oral liquid formulations. Eur. J. Hosp. Pharm. 2017;25:e98–e101. doi: 10.1136/ejhpharm-2017-001281.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/ejhpharm-2017-001281</ArticleId>
            <ArticleId IdType="pmc">PMC6319418</ArticleId>
            <ArticleId IdType="pubmed">31157077</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sharley N.A., Yu A.M.C., Williams D.B. Stability of Mixtures Formulated from Warfarin Tablets or Powder. J. Pharm. Pract. Res. 2007;37:95–97. doi: 10.1002/j.2055-2335.2007.tb00026.x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/j.2055-2335.2007.tb00026.x</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>European Pharmacopoeia 10.5  04/2014:0698. Warfarin Sodium.  [(accessed on 21 February 2021)].  Available online:  https://pheur.edqm.eu/internal/a4057e4bf5d940ea9a33865406166d09/10-5/10-5/page/0698E.pdf.</Citation>
        </Reference>
        <Reference>
          <Citation>Amalanathan M., Joe I.H., Kostova I. Density functional theory calculation and vibrational spectral analysis of 4-hydroxy-3-(3-oxo-1-phenylbutyl)-2H-1-benzopyran-2-one. J. Raman Spectrosc. 2010;41:1076–1084. doi: 10.1002/jrs.2543.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/jrs.2543</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kostova I., Amalanathan M., Hubert Joe I. Molecular first order hyperpolarizability and vibrational spectral investigation of Warfarin sodium. Chem. Phys. 2010;378:88–102. doi: 10.1016/j.chemphys.2010.10.008.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.chemphys.2010.10.008</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nguyenpho A., Ciavarella A.B., Siddiqui A., Rahman Z., Akhtar S., Hunt R., Korang-Yeboah M., Khan M.A. Evaluation of In-Use Stability of Anticoagulant Drug Products: Warfarin Sodium. J. Pharm. Sci. 2015;104:4232–4240. doi: 10.1002/jps.24657.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/jps.24657</ArticleId>
            <ArticleId IdType="pubmed">26501849</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Imperial College of Science, Technology and Medicine, Department of Chemistry  Warfarin.  [(accessed on 14 October 2021)].  Available online:  https://www.ch.ic.ac.uk/local/projects/bhonoah/characterisation.html.</Citation>
        </Reference>
        <Reference>
          <Citation>Nowak P., Olechowska P., Mitoraj M., Woźniakiewicz M., Kościelniak P. Determination of acid dissociation constants of warfarin and hydroxywarfarins by capillary electrophoresis. J. Pharm. Biomed. Anal. 2015;112:89–97. doi: 10.1016/j.jpba.2015.04.027.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jpba.2015.04.027</ArticleId>
            <ArticleId IdType="pubmed">25968611</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chemistry Resources  How to Measure pKa by UV-Vis Spectrophotometry.  [(accessed on 13 April 2021)].  Available online:  http://www.chemagine.co.uk/resources/pka.htm.</Citation>
        </Reference>
        <Reference>
          <Citation>Middelburg J.J.  Late Cretaceous/Paleogene West Antarctica Terrestrial Biota and Its Intercontinental Affinities. Springer International Publishing; Berlin/Heidelberg, Germany: 2019. Biogeochemical Processes and Inorganic Carbon Dynamics; pp. 77–105.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/978-3-030-10822-9_5</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>McIlvaine T. A buffer solution for colorimetric comparison. J. Biol. Chem. 1921;49:183–186. doi: 10.1016/S0021-9258(18)86000-8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0021-9258(18)86000-8</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
